Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

American journal of respiratory and critical care medicine - 1 Nov 1999

Dirksen A, Dijkman J H, Madsen F, Stoel B, Hutchison D C, Ulrik C S, Skovgaard L T, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman H A, Reiber J H, Hansen N C, Heckscher T, Viskum K, Stolk J

Abstract excerpt

We have investigated whether restoration of the balance between neutrophil elastase and its inhibitor, alpha(1)-antitrypsin, can prevent the progression of pulmonary emphysema in patients with alpha(1)-antitrypsin deficiency. Twenty-six Danish and 30 Dutch ex-smokers with alpha(1)-antitrypsin deficiency of PI*ZZ phenotype and moderate emphysema (FEV(1) between 30% and 80% of predicted) participated in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to alpha 1-Antitrypsin Deficiency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Forced Expiratory Volume

Share to Pulmonary Emphysema

Share to Spirometry

Share to Tomography, X-Ray Computed

Share to Vital Capacity

Source

Identifiers

PMID: 10556107
DOI: 10.1164/ajrccm.160.5.9901055

Genes

FEV

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.PMID 10556107Read ↗

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.Semantic proximity Read ↗

[Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].Semantic proximity Read ↗

[Alpha-1-antitrypsin deficiency - an update].Semantic proximity Read ↗

Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.Semantic proximity Read ↗

Alpha-1 Antitrypsin Augmentation TherapySemantic proximity Read ↗

Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.Semantic proximity Read ↗

Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.Semantic proximity Read ↗

Progression and Augmentation Therapy in PiSZ and PiZZ Alpha-1 Antitrypsin Deficiency: A Longitudinal Functional and Densitometric Study.Semantic proximity Read ↗

Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline.Semantic proximity Read ↗

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.Semantic proximity Read ↗

Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.Semantic proximity Read ↗

Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.